Nordic Nanovector to Conduct a Comprehensive Review and Independent Data Evaluation of PARADIGME, its Phase 2b Trial with Betalutin® in R/R FL as a Result of Continuing Slow Recruitment ...Middle East

OSLO, Norway, June 2, 2022 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV) today provides an update on PARADIGME, its ongoing Phase 2b trial of Betalutin® (177Lu lilotomab satetraxetan) in 3rd-line relapsed rituximab/anti-CD20 refractory follicular lymphoma (3L R/R FL). As highlighted...

Hence then, the article about nordic nanovector to conduct a comprehensive review and independent data evaluation of paradigme its phase 2b trial with betalutin in r r fl as a result of continuing slow recruitment was published today ( Thursday 02/06/2022 - 08:40 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Nordic Nanovector to Conduct a Comprehensive Review and Independent Data Evaluation of PARADIGME, its Phase 2b Trial with Betalutin® in R/R FL as a Result of Continuing Slow Recruitment )

Also on site :

• Stunning ISS Photo of Florida, Cuba Captures & 039;Moonglint& 039;
• Saudi-led coalition strikes Yemeni port over unauthorised weapons shipment
• Will Cristiano Ronaldo play tonight for Al-Nassr vs Al Ettifaq in SPL 2025-26?